Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma.

Abstract

The modulation of subpopulations of pro-angiogenic monocytes (VEGFR-1+CD14 and Tie2+CD14) was analyzed in an ancillary study from the prospective PazopanIb versus Sunitinib patient preferenCE Study (PISCES) (NCT01064310), where metastatic renal cell carcinoma (mRCC) patients were treated with two anti-angiogenic drugs, either sunitinib or pazopanib. Blood samples from 86 patients were collected prospectively at baseline (T1), and at 10 weeks (T2) and 20 weeks (T3) after starting anti-angiogenic therapy. Various subpopulations of myeloid cells (monocytes, VEGFR-1+CD14 and Tie2+CD14 cells) decreased during treatment. When patients were divided into two subgroups with a decrease (defined as a >20% reduction from baseline value) (group 1) or not (group 2) at T3 for VEGFR-1+CD14 cells, group 1 patients presented a median PFS and OS of 24 months and 37 months, respectively, compared with a median PFS of 9 months (p = 0.032) and a median OS of 16 months (p = 0.033) in group 2 patients. The reduction in Tie2+CD14 at T3 predicted a benefit in OS at 18 months after therapy (p = 0.04). In conclusion, in this prospective clinical trial, a significant decrease in subpopulations of pro-angiogenic monocytes was associated with clinical response to anti-angiogenic drugs in patients with mRCC.

• Authors: Stephane Oudard, Nadine Benhamouda, Bernard Escudier, Patrice Ravel, Thi Tran, Emeline Levionnois, Sylvie Negrier, Philippe Barthelemy, Jean François Berdah, Marine Gross-Goupil, Cora N Sternberg, Petri Bono, Camillo Porta, Ugo De Giorgi, Omi Parikh, Robert Hawkins, Martin Highley, Jochen Wilke, Thomas Decker, Corinne Tanchot, Alain Gey, Magali Terme, Eric Tartour
• Journal: Cells (Cells) Vol. 11 Issue 1 (12 22 2021) ISSN: 2073-4409 [Electronic] Switzerland
• PMID: 35011579 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Angiogenesis Inhibitors
• Antigens, CD
• Vascular Endothelial Growth Factor Receptor-1
• Sunitinib

Topics

• Angiogenesis Inhibitors (pharmacology, therapeutic use)
• Animals
• Antigens, CD (metabolism)
• Carcinoma, Renal Cell (blood, blood supply, drug therapy, pathology)
• Disease Models, Animal
• Humans
• Kidney Neoplasms (blood, blood supply, drug therapy, pathology)
• Mice, Inbred BALB C
• Monocytes (pathology)
• Myeloid Cells (drug effects, pathology)
• Neoplasm Metastasis
• Neovascularization, Pathologic (drug therapy)
• Sunitinib (pharmacology, therapeutic use)
• Treatment Outcome
• Vascular Endothelial Growth Factor Receptor-1 (metabolism)
• Mice